{"filing":{"accession_number":"0001213900-26-111174","cik":"0001985062","ticker":"PBMWW","company_name":"PSYENCE BIOMEDICAL LTD.","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"ea0309190-6k_psyence.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390026111174/ea0309190-6k_psyence.htm"},"events":[{"id":36573,"run_id":33720,"accession_number":"0001213900-26-111174","anchor_item_number":"EX-99.1","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This press release announces completion of a US$2.6 million investment by Psyence BioMed in its related party PsyLabs upon achievement of specified milestones (regulatory readiness documentation and cGMP manufacturing agreement with Benuvia). The investment is material to shareholders as it represents a significant capital deployment, increases the Company's stake in PsyLabs from 41.13% to 43.37%, and advances the Company's ibogaine development program. While the investment itself is a financial transaction, it does not fit neatly into the specific financial event categories (debt_issuance, dividend_distribution, dilutive_issuance, material_impairment, or ma_activity), making financial_other the most appropriate classification.","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41032,"accession_number":"0001213900-26-111174","item_number":"EX-99.1","item_title":"ea030919001ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This press release announces completion of a US$2.6 million investment by Psyence BioMed in its related party PsyLabs upon achievement of specified milestones (regulatory readiness documentation and cGMP manufacturing agreement with Benuvia). The investment is material to shareholders as it represents a significant capital deployment, increases the Company's stake in PsyLabs from 41.13% to 43.37%, and advances the Company's ibogaine development program. While the investment itself is a financial transaction, it does not fit neatly into the specific financial event categories (debt_issuance, dividend_distribution, dilutive_issuance, material_impairment, or ma_activity), making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:00:38.213138+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41032,"accession_number":"0001213900-26-111174","item_number":"EX-99.1","item_title":"ea030919001ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This press release announces completion of a US$2.6 million investment by Psyence BioMed in its related party PsyLabs upon achievement of specified milestones (regulatory readiness documentation and cGMP manufacturing agreement with Benuvia). The investment is material to shareholders as it represents a significant capital deployment, increases the Company's stake in PsyLabs from 41.13% to 43.37%, and advances the Company's ibogaine development program. While the investment itself is a financial transaction, it does not fit neatly into the specific financial event categories (debt_issuance, dividend_distribution, dilutive_issuance, material_impairment, or ma_activity), making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:00:38.213138+00:00","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-10-21"}]}